Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, June 3rd. Analysts expect Anixa Biosciences to post earnings of ($0.10) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01.

Anixa Biosciences Trading Down 1.5%

Anixa Biosciences stock traded down $0.04 during trading on Friday, reaching $2.57. The company had a trading volume of 18,463 shares, compared to its average volume of 89,521. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $4.20. The firm's 50-day simple moving average is $2.68 and its 200 day simple moving average is $2.80. The firm has a market capitalization of $82.75 million, a price-to-earnings ratio of -6.59 and a beta of 0.43.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANIX. Maxim Group began coverage on Anixa Biosciences in a report on Friday, March 21st. They issued a "buy" rating and a $10.00 target price on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Thursday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, March 25th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.